Summary:
- This article, published in *Nature Reviews Nephrology*, provides a comprehensive clinical overview of the current management strategies and emerging therapeutic targets for IgA nephropathy.
- The authors synthesize recent breakthroughs in understanding the pathogenesis of the disease—specifically the multi-hit hypothesis involving galactose-deficient IgA1—and evaluate how these insights are translating into novel precision medicine approaches for patients.